Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Thursday's Featured News Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsAuthored by Nathan Reiff. Article Posted: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Many companies take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, several promising treatments have shown significant potential—and with that comes the possibility of sizeable sales. Two smaller biotech companies are seeing notable share-price momentum thanks to their leading oncology drugs. Besides offering strong therapeutic potential, these medicines could help the firms move beyond penny-stock (or otherwise unstable) status and toward long-term profitability. Both remain high-risk investments, but they also carry the potential for outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% during a week when the S&P 500 fell roughly 1%. The rally helped IOVA more than double year-to-date (YTD). Still, with a consensus price target of $8.88, Wall Street expects more from the stock—that target implies about 71% upside from current levels. The primary catalyst for Iovance's move is its lead therapy, Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States since 2024 and is gaining traction, with additional approvals likely in the E.U., U.K., and elsewhere. When used with Proleukin, Iovance's IL-2 immunotherapy, management projects U.S. peak sales above $1 billion. Its broader upside may lie outside melanoma: Amtagvi received FDA Fast Track designation for non-small cell lung cancer and may be effective against other tumor types. Iovance's outperformance was also supported by its Q4 2025 earnings report, released in late February, which showed smaller-than-expected losses per share and $5 million in revenue. For the full year, revenue rose roughly 30% year-over-year. Iovance is a small-cap (about $2 billion) biotech and, despite the rally, remains a penny stock; analysts remain cautious—about half of its roughly dozen ratings are Hold or Sell. Risks are elevated: beyond the typical uncertainties facing smaller biotechs, Amtagvi is a personalized therapy that is costly and complex to manufacture, which could constrain margins and slow the firm's path to profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its YTD performance dwarfs Iovance's. IBRX shares are up nearly 300% in 2026 alone, and this may be only the beginning. Analysts' consensus target of $13.60 implies roughly 70% upside from current levels. ImmunityBio's primary growth driver is Anktiva, a treatment for specific types of bladder cancer. In February, shares spiked after the E.U. regulator granted the drug conditional marketing authorization, the latest in a string of approvals worldwide. Anktiva drove $113 million in sales last year, roughly a 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in additional cancer indications, and ImmunityBio is actively exploring those possibilities. Despite the surge over recent quarters, IBRX remains a speculative and risky investment. The company posted a full-year net loss of $351 million for 2025 as R&D expenses continue to mount. Still, Wall Street appears somewhat more optimistic on ImmunityBio than on Iovance: six of seven analysts rate the shares a Buy or equivalent.
| 
